The last day of 2012

DAC Biotech was founded in Hangzhou.

2013

Established a R&D center

2014
One of the first batch of Leading Entrepreneurial Innovation Teams in Zhejiang Province

2015

Second place in the nation-wide Innovation and Entrepreneurship Competition in China

Round Pre-A financing

2016

Built the first pilot production line

2017

Round A financing

2018

The project of DAC-002 was selected as a Major Technological Innovation Project in Hangzhou.

2019

Round Bfinancing 

Clinical trial of DX126-262 initiated

The project of DX126-262 was selected as a National Major Technological Innovation Project

2020

Built the second pilot production lineDAC-002 was approved by NMPA to enter clinical trials

Formed a strategic partnership with Shanghai Junshi Biosciences Clinical trial of DAC-002 initiated by Junshi Biosciences with drugs produced in DAC Biotechnology.

2021

Round C financing;

DX126-262 was approved by FAD to proceed  clinical studies in the US Initiate multi-center phase II clinical trials of DX126-262 in several countries;

DXC-005 was approved by NMPA to enter clinical trials, began clinical trials of DXC-005 

2023

Expected moving into our new R&D and Production facilities, and further expanding the company’s research, development and manufacture capacity.